Mitophagy Receptor Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mitophagy is a specialized form of autophagy that selectively removes damaged or dysfunctional mitochondria through autophagic degradation. This process is critical for maintaining mitochondrial quality control and cellular homeostasis, and its dysfunction has been strongly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@massaga2025]
```mermaid
flowchart TD
A["Mitochondrial Damage"] --> B["Mitochondrial Membrane Potential Loss"]
B --> C["PINK1 Stabilization on OMM"]
C --> D["Parkin Recruitment to OMM"]
D --> E["Ubiquitin Chain Synthesis"]
E --> F["Autophagy Receptor Recruitment"]
F --> G["p62/SQSTM1 Binding"]
F --> H["OPTN Binding"]
F --> I["NDP52 Binding"]
F --> J["TAX1BP1 Binding"]
G --> K["LC3/GABARAP Lipidation"]
H --> K
I --> K
J --> K
K --> L["Phagophore Expansion"]
L --> M["Mitophagosome Formation"]
M --> N["Lysosomal Fusion"]
N --> O["Mitolysosome Formation"]
O --> P["Mitochondrial Degradation"]
Mitophagy Receptor Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mitophagy is a specialized form of autophagy that selectively removes damaged or dysfunctional mitochondria through autophagic degradation. This process is critical for maintaining mitochondrial quality control and cellular homeostasis, and its dysfunction has been strongly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@massaga2025]
| Protein | Gene | Function | Disease Relevance | [@tang2024]
|---------|------|----------|-------------------| [@abraham2024]
| PINK1 | PARK6 | Serine/threonine-protein kinase that accumulates on damaged mitochondria | PD: Loss-of-function mutations cause early-onset PD | [@morgan2024]
| Parkin | PARK2 | E3 ubiquitin ligase recruited to damaged mitochondria | PD: Loss-of-function mutations cause early-onset PD | [^6]
| MFN1/2 | MFN1/MFN2 | Mitofusins mediating mitochondrial fusion | Mitochondrial dynamics | [^7]
| TOMM20 | TOMM20 | Outer mitochondrial membrane translocase receptor | Mitochondrial protein import | [^8]
| p62/SQSTM1 | SQSTM1 | [Autophagy](/entities/autophagy) receptor binding ubiquitin and LC3 | ALS: p62 inclusions in motor [neurons](/entities/neurons) | [^9]
| OPTN | OPTN | Autophagy receptor with UBAN domain | ALS: OPTN mutations cause ALS/FTD | [^10]
| NDP52 | CALCOCO2 | Selective autophagy receptor for bacteria and mitochondria | ALS: NDP52 aggregates | [@lazarou2019]
| TAX1BP1 | TAX1BP1 | Autophagy receptor for mitophagy | Neuroinflammation | [^12]
| LC3 | MAP1LC3A/B/C | Autophagosome marker, conjugated to phosphatidylethanolamine | Core autophagy machinery | [@caccamo2019]
| GABARAP | GABARAP | GABA receptor-associated protein, autophagy | Core autophagy machinery | [@damico2023]
| LAMP2 | LAMP2 | Lysosomal-associated membrane protein | Danon disease, lysosomal function | [@ryu2023]
| BNIP3 | BNIP3 | BH3-only protein, mitophagy receptor | Hypoxia-induced mitophagy | [@wang2023]
| NIX | BNIP3L | NIP3-like protein X, mitophagy receptor | Reticulocyte maturation | [@urolithin2023]
| FUNDC1 | FUNDC1 | FUN14 domain-containing protein 1 | Hypoxia-sensitive mitophagy | [@bjrky2020]
| Ambra1 | AMBRA1 | Activating molecule in Beclin 1-regulated autophagy | Developmental mitophagy | [@kanki2019]
Under normal conditions, PINK1 (PTEN-induced kinase 1) is imported into mitochondria through the TOM/TIM complex and rapidly degraded by proteases. However, when mitochondria lose their membrane potential (Δψm), PINK1 cannot be imported and instead accumulates on the outer mitochondrial membrane (OMM). [@wei2024]
Accumulated PINK1 undergoes autophosphorylation at Ser228 and Ser402, activating its kinase domain. Active PINK1 then phosphorylates both ubiquitin and Parkin.
Phospho-ubiquitin (pSer65-Ub) recruits Parkin (encoded by PRKN) from the cytosol. PINK1 directly phosphorylates Parkin at Ser65 in its Ubl domain, activating its E3 ubiquitin ligase activity.
Active Parkin catalyzes the synthesis of diverse ubiquitin chains on OMM proteins. Key substrates include:
Ubiquitin chains serve as binding sites for autophagy receptors containing both ubiquitin-binding domains (UBDs) and LC3-interacting regions (LIRs):
Autophagy receptors simultaneously bind ubiquitinated mitochondria and LC3/GABARAP family proteins on the growing phagophore. This recruits the membrane to damaged mitochondria and drives the expansion of the isolation membrane.
The completed mitophagosome fuses with lysosomes through the action of SNARE proteins, VAMP8, and STX17, forming a mitolysosome where mitochondria are degraded by acidic hydrolases.
BNIP3 (Bcl-2/adenovirus E1B 19kDa interacting protein 3) and its homolog NIX (BNIP3L) are BH3-only proteins that can directly induce mitophagy through:
This pathway is particularly important for:
FUNDC1 (FUN14 domain-containing protein 1) is an OMM protein that acts as a receptor for hypoxia-induced mitophagy:
Ambra1 (activating molecule in Beclin 1-regulated autophagy) is a positive regulator of autophagy that:
Amyloid-beta effects on mitophagy:
Genetic forms:
SOD1 mutations:
| Compound | Mechanism | Development Stage | Reference |
|----------|-----------|-------------------|-----------|
| Urolithin A | Activates mitophagy via [mTOR](/mechanisms/mtor-signaling-pathway)-independent mechanism | Phase 3 clinical trials | PMID: 35472254(https://pubmed.ncbi.nlm.nih.gov/35472254/) |
| NAD+ precursors (NR, NMN) | Sirt1 activation, enhances mitophagy | Preclinical/Phase 2 | PMID: 33268791(https://pubmed.ncbi.nlm.nih.gov/33268791/) |
| Rapamycin | mTORC1 inhibition | Preclinical | PMID: 16759985(https://pubmed.ncbi.nlm.nih.gov/16759985/) |
| Metformin | AMPK activation | Phase 2 for AD | PMID: 30676198(https://pubmed.ncbi.nlm.nih.gov/30676198/) |
| Resveratrol | SIRT1 activation | Preclinical | PMID: 26460472(https://pubmed.ncbi.nlm.nih.gov/26460472/) |
Mitophagy is intimately connected to mitochondrial fusion (MFN1/2, OPA1) and fission (DRP1). Damaged mitochondria are first separated through fission before being targeted for mitophagy.
The study of Mitophagy Receptor Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent publications highlighting key advances in this mechanism:
🟡 Moderate Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 20 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 49%
The following diagram shows the key molecular relationships involving Mitophagy Receptor Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: